Identification of discrete prognostic groups in Ewing sarcoma Journal Article


Authors: Karski, E. E.; McIlvaine, E.; Segal, M. R.; Krailo, M.; Grier, H. E.; Granowetter, L.; Womer, R. B.; Meyers, P. A.; Felgenhauer, J.; Marina, N.; DuBois, S. G.
Article Title: Identification of discrete prognostic groups in Ewing sarcoma
Abstract: Background: Although multiple prognostic variables have been proposed for Ewing sarcoma (EWS), little work has been done to further categorize these variables into prognostic groups for risk classification. Procedure: We derived initial prognostic groups from 2,124 patients with EWS in the SEER database. We constructed a multivariable recursive partitioning model of overall survival using the following covariates: age; stage; race/ethnicity; sex; axial primary; pelvic primary; and bone or soft tissue primary. Based on this model, we identified risk groups and estimated 5-year overall survival for each group using Kaplan-Meier methods. We then applied these groups to 1,680 patients enrolled on COG clinical trials. Results: A multivariable model identified five prognostic groups with significantly different overall survival: (i) localized, age <18 years, non-pelvic primary; (ii) localized, age <18, pelvic primary or localized, age ≥18, white, non-Hispanic; (iii) localized, age ≥18, all races/ethnicities other than white, non-Hispanic; (iv) metastatic, age <18; and (v) metastatic, age ≥18. These five groups were applied to the COG dataset and showed significantly different overall and event-free survival based upon this classification system (P<0.0001). A sub-analysis of COG patients treated with ifosfamide and etoposide as a component of therapy evaluated these findings in patients receiving contemporary therapy. Conclusions: Recursive partitioning analysis yields discrete prognostic groups in EWS that provide valuable information for patients and clinicians in determining an individual patient's risk of death. These groups may enable future clinical trials to adjust EWS treatment according to individualized risk. © 2015 Wiley Periodicals, Inc.
Keywords: adolescent; adult; cancer chemotherapy; event free survival; unclassified drug; major clinical study; overall survival; cancer staging; etoposide; ifosfamide; ewing sarcoma; high risk population; ethnicity; clinical trial (topic); recursive partitioning; cancer prognosis; human; male; female; priority journal; article; prognostic groups
Journal Title: Pediatric Blood and Cancer
Volume: 63
Issue: 1
ISSN: 1545-5009
Publisher: Wiley Periodicals, Inc  
Date Published: 2016-01-01
Start Page: 47
End Page: 53
Language: English
DOI: 10.1002/pbc.25709
PROVIDER: scopus
PUBMED: 26257296
PMCID: PMC5011751
DOI/URL:
Notes: Article -- Export Date: 3 February 2016 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Paul Meyers
    311 Meyers